uniQure (QURE) has provided an update.
uniQure N.V. has released promising interim results from its Phase I/II clinical trials of AMT-130, a gene therapy aimed at treating Huntington’s disease. Data from patients in both U.S. and European trials show a significant slowing in disease progression, particularly in those receiving a high dose of the therapy. Additionally, there was a notable reduction in neurofilament light chain levels, an important biomarker of neurodegeneration. AMT-130 has maintained a good safety profile with no serious adverse events related to the treatment reported. These encouraging findings suggest potential for AMT-130 to change the management of Huntington’s disease.
See more insights into QURE stock on TipRanks’ Stock Analysis page.
